张定校，生命医学交叉研究院教授、岳麓学者、博士生导师、湖南省杰出青年基金获得者。2010年于韩国忠北国立大学获得博士学位。随后分别在美国辛辛那提大学医学院和德州大学MD安德森癌症中心从事博士后研究；2015年在MD安德森癌症中心任青年研究员Instructor；2016年在美国罗斯威尔帕克癌症研究所任助理教授。2019年加入湖南大学生命医学交叉研究院，聘为教授、岳麓学者。回国前主持美国NIH/NCI-R21基金一项；回国后主持国家自然科学基金-面上和湖南省“杰出青年”等项目。近年来相关研究成果（主要为第一或通讯作者身份）发表在Nature子刊Nat Commun (2020, 2018, 2017, 2016, IF=17.694)和Cell子刊Trends in Cancer (2018 IF=19.161), Stem Cell Rep (2018 IF=7.294),及Science子刊Science Advances (2024, IF=13.6)，以及其他国际杂志Angew Chem (2024, IF=16.04), Oncogene (2024, IF=8.0), GPB (2024, IF=11.5), Cancer Lett (2024, IF=9.756), J Immunother Cancer (2023, IF=12.485), Cell Mol Life Sci (2024, 2021 IF=9.21), J Hemat & Oncol (2021 IF=23.168), Semin Cancer Biol (2018 IF=17.01), Clin Cancer Res (2016 IF=13.8), EBioMedicine (2018 IF=11.205), Stem Cells Transl Med (2017 IF=7.655), Cell Discov (2016 IF=38.08)上。目前担任Nat Commun, Cell Reports, STTT, APSB, Advanced Science, Theranostics, EBioMedicine, Genom Proteom & Bioinform, Oncogene, Stem Cells Transl Med, Stem Cells, Epigenomics, Oncogenesis等多家国际期刊审稿人。

2019.07 -至今，湖南大学，生命医学交叉研究院，教授

2018.09 - 2019.07，华中农业大学，生物医学中心，教授

2016.06 - 2018.12，美国Roswell Park Cancer Center，助理教授(Assistant Professor of Oncology)

2015.04 - 2016.05，美国MD Anderson Cancer Center，讲师(Instructor)

2012.02 - 2015.03，美国MD Anderson Cancer Center，博士后

2010.04 - 2012.02，美国University of Cincinnati College of Medicine，博士后

2006.09 - 2010.02，忠北国立大学，分子胚胎发育学，博士

2003.09 - 2006.06，华中农业大学，分子生物学，硕士

1999.09 - 2003.06，华中农业大学，动物科学，本科

[1]2018-2020，NIH/NCI – R21前列腺癌干细胞与临床治疗, $47.2万，主持（已结题）

[2]2019-2021，武汉市科技计划项目–生物医学专项, 50万,主持（已结题）

[3]2020-2023，国家自然科学基金-面上，55万，主持（已结题）

[4]2021-2023，湖南省杰出青年基金，50万，主持（已结题）

[5]2022-2024，深圳市自然科学基金-面上，30万，主持

[6]2024-2026，广东省自然科学基金-面上，15万，主持

[7]2025-2028，国家自然科学基金-面上，50万，主持

[8]2025-2027，广东省自然科学基金-面上，10万，主持

[9]2019-2027，湖南大学 高层次人才启动基金，主持

发表论文：

[1]He Q., Zhang Y., Li W., Chen S., Xiong J., Zhao R., Yuan K., Hu Q., Liu S., Gao G., Bedford MT., Tang DG, Xu B*., Zou C*., Zhang D*. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. Cancer Letters, 2024, 602: 217214. IF=9.756

[2]C. Zou, J. Zhu, J. Xiong, Y. Tian, Y. Peng, E. Cheung, D. Zhang*. Comprehensive characterization of the integrin family across 32 cancer types. Genomics, Proteomics & Bioinformatics (IF=11.5), 2024, May 09, https://doi.org/10.1093/gpbjnl/qzae035.

[3]Feng Y., Li Z., He L., Zhu J., Zou C., Tian Y., Xiong J., He Q., Li W., Xu H., Liu L., Xu B., Shi J*., Zhang D*. Stabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3. Cellular and Molecular Life Sciences, 2024, 2024 Oct 5;81(1):414. IF=9.261

[4]Z. Li, Y. Feng, H. Han, X. Jiang, W. Chen, X. Ma, Y. Mei, D. Yuan, D. Zhang*, J. Shi*. A Stapled Peptide Inhibitor Targeting the Binding Interface of N6-Adenosine-Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy. Angew Chem Int Ed Engl (IF=16.04). 2024 Apr 12:e202402611.

[5]Han H, Li Z, Feng Y, Song H, Fang Z, Zhang D, Yuan D, Shi J. Peptide Degrader-Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma. Angew Chem Int Ed Engl (IF=16.04). 2024 Aug 13:e202407381.

[6]C. Zou, W. Li, Y. Zhang, N. Feng, S. Chen, L. Yan, Q. He, K. Wang, W. Li, Y. Li, Y. Wang, B. Xu*, and D. Zhang*. Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation. Science Advances (IF=13.6), 2024, Apr 5;10(14):eadm7098.

[7]M. Chen, C. Zou*, Y. Tian, D. Zhang*. An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer. Oncogene (IF=9.867), 2024, Apr 2. doi: 10.1038/s41388-024-03011-6

[8]Chen S., Lu K., Hou Y., You Z., Shu C., Wei X., Wu T., Shi N., Zhang G., Wu J., Chen S., Zhang L., Li W., Zhang D*., Ju S*., Chen M*., Xu B*. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. The Journal for ImmunoTherapy of Cancer, 2023 11(4):e006020. IF=12.495

[9]Zou C., He Q., He L., Feng YQ., Chen MJ., Zhang D*. A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response. NAR Cancer, 2022 4(1):zcac010. IF=5.1

[10]Xiong JL, Yan LL, Zou C, Wang K, Chen M, Xu B*, Zhou ZZ*, Zhang D*. Integrins Regulate Stemness in Solid Tumor: An Emerging Therapeutic Target. Journal of Hematology & Oncology, 2021, 14(1):177. IF=23.168

[11]Zhang D.,* Hu Q., Liu XZ, Ji YB, Kirk J., Wang JM., Liu S., Tang DG*. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nature Communications, 2020 11(1):2089. IF=17.694

[12]Zou C., Wan Y., He L., Zheng J., Mei Y., Shi J., Zhang M., Dong Z., Zhang D*. RBM38 in Cancer: Role and Mechanism. Cellular and Molecular Life Sciences, 2021 78(1):117-128. IF=9.261

[13]Zhang D.,* Zhao SH., Li XY., Kirk J., Tang DG*. Prostate Luminal Progenitors in Development and Cancer. Trends in Cancer, 2018, 4(11):769-783. IF=19.161

[14]Zhang D*, Tang DG. "Splice" a way towards neuroendocrine prostate cancer. EBioMedicine, 2018, pii: S2352-3964(18)30331-1. IF=11.205

[15]Zhang D.,* Tang DG* and Rycaj K*. Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Seminars in Cancer Biology, 2018, (17)30280-8 IF=17.012

[16]Zhang D*., Gong S., Lu Y., Jeter C., Tang DG*. Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration. Stem Cell Reports, 2018, 10(1):228–242. IF=7.294

[17]Zhang, D*., Lin, K., Lu, Y., Rycaj, K., Zhong, Y., Chao, H.P., Davis, T., Shen, J., and Tang, D.G*. Developing a novel 2D culture system to enrich human prostate luminal progenitors that can function as a cell of origin for prostate cancer. Stem Cells Translational Medicine, 2017, 6(3): 748-760. IF=7.655

[18]Zhang, D*., Park, D., Zhong, Y., Lu, Y., Gong, S., Chen, X., Liu, X., Chao, H.P., Whitney, P., Davis, T., Takata, Y., Shen, J., Iyer, V.R., Tang, D.G*. Stem cell and neurogenic gene expression profiles link prostate basal cells to aggressive prostate cancer. Nature Communications, 2016, 7:10798. IF=17.694

[19]Liu C#., Liu R#., Zhang D., Deng Q., Liu B., Chao HP., Rycaj K., Takata Y., Lin K., Lu Y., Zhong Y., Krolewski J., Shen J., and Tang D*. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nature Communications, 2017, 8:14270. IF=17.694

更多论文发表链接NCBI: https://www.ncbi.nlm.nih.gov/myncbi/1r9DwycZd6wA_/bibliography/public/